Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

CYCCP

Cyclacel Pharms

NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.65

0.00

0.00%

Opening 09:30 05/07 EDT

OPEN

7.65

PREV CLOSE

7.65

HIGH

7.65

LOW

7.65

VOLUME

TURNOVER

52 WEEK HIGH

9.65

52 WEEK LOW

4.810

MARKET CAP

30.65M

P/E (TTM)

-1.7583

Cyclacel Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Business Update

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter financial results and provide a business update...

GlobeNewswire · 2d ago

BRIEF-Sphera Funds Management Ltd Reports 6.29% Passive Stake In Cyclacel Pharmaceuticals As Of March 12

reuters.com · 03/18 17:03

Cyclacel To Present At Oppenheimer 31st Annual Healthcare Conference Mar. 18 At 9:20 a.m. ET

BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", , Cyclacel", , or the ", , Company", , )))), a biopharmaceutical company developing

Benzinga · 03/15 11:18

BRIEF-Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering Of Common Stock

reuters.com · 03/12 14:26

Cyclacel Pharmaceuticals Prices 1,807,143 Share Common Stock Offering At $7/Share

BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", , Cyclacel", , or the ", , Company", , )))), a biopharmaceutical company

Benzinga · 03/12 13:33

BRIEF-Cyclacel Pharmaceuticals Announces Proposed Public Offering Of Common Stock

reuters.com · 03/11 21:59

BRIEF-Cyclacel Pharma Reports Q4 And Full Year 2020 Financial Results

reuters.com · 02/25 23:54

Cyclacel Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 25, 2021 / Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 25, 2021 at 4:30 PM Eastern Time.

ACCESSWIRE · 02/25 19:30

Forecast

No Data

Income StatementMore

Net Income (USD)

YoY (%)

Balance SheetMore

Total Assets (USD)

Total Liabilities (USD)

Debt to Asset (%)

Cash FlowMore

Operating (USD)

YoY (%)

Learn about the latest financial forecast of CYCCP. Analyze the recent business situations of Cyclacel Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.

No Data

Performance
Asset Allocation
Dividend History

No Data

Industry

Biotechnology & Medical Research

+1.36%

Pharmaceuticals & Medical Research

+0.97%

Key Executives

Chairman/Director

David U'Prichard

President/Chief Executive Officer/Director

Spiro Rombotis

Vice Chairman/Director

Christopher Henney

Chief Financial Officer/Chief Operating Officer/Executive Vice President - Finance/Secretary/Director

Paul McBarron

Senior Vice President

Mark Kirschbaum

Director

Brian Schwartz

Director

Karin Walker

Independent Director

Samuel Barker

Independent Director

Gregory Hradsky

Independent Director

Lloyd Sems

Independent Director

Robert Spiegel

Declaration Date Dividend Per Share Ex-Div Date: --
Dividend USD 0.15
04/15/2021; 12/11/2020
Dividend USD 0.15
01/14/2021; 09/10/2020
Dividend USD 0.15
10/15/2020; 06/25/2020
Dividend USD 0.15
07/16/2020; 03/11/2020
Dividend USD 0.15
04/14/2020; 12/10/2019
Dividend USD 0.15
01/16/2020; 09/05/2019
Dividend USD 0.15
10/10/2019; 05/29/2019
Dividend USD 0.15
07/11/2019; 03/07/2019
Dividend USD 0.15
04/12/2019; 12/11/2018
Dividend USD 0.15
01/11/2019; 09/06/2018
Dividend USD 0.15
10/12/2018; 05/31/2018
Dividend USD 0.15
07/12/2018; 03/07/2018
Dividend USD 0.15
04/10/2018; 12/06/2017
Dividend USD 0.15
01/11/2018; 09/07/2017
Dividend USD 0.15
10/12/2017; 05/30/2017
Dividend USD 0.15
07/12/2017; 03/07/2017
Dividend USD 0.15
04/11/2017; 12/07/2016
Dividend USD 0.15
01/13/2017; 09/06/2016
Dividend USD 0.15
10/13/2016; 05/26/2016
Dividend USD 0.15
07/13/2016; 03/29/2016
Dividend USD 0.15
04/14/2016; 12/24/2015
Dividend USD 0.15
01/19/2016; 10/14/2015
Dividend USD 0.15
10/21/2015; 05/22/2015
Dividend USD 0.15
07/15/2015; 02/18/2015
Dividend USD 0.15
04/15/2015; 12/03/2014
Dividend USD 0.15
12/31/2014; 05/22/2014
Dividend USD 0.15
06/27/2014; 03/17/2014
Dividend USD 0.15
04/15/2014; 12/04/2013
Dividend USD 0.15
01/15/2014; 09/10/2013
Dividend USD 0.15
10/17/2013; 07/08/2013
Dividend USD 0.15
07/18/2013; 04/05/2013
Dividend USD 0.15
04/17/2013; 01/11/2013
Dividend USD 0.15
01/17/2013; 04/11/2011
Dividend USD 0.15
04/19/2011; 01/11/2011
Dividend USD 0.15
01/19/2011; 01/07/2009
Dividend USD 0.15
01/14/2009; 10/07/2008
Dividend USD 0.15
10/16/2008; 07/01/2008
Dividend USD 0.15
07/16/2008; 04/08/2008
Dividend USD 0.15
04/16/2008; 12/06/2007
Dividend USD 0.15
01/16/2008; 09/04/2007
Dividend USD 0.15
10/17/2007; 07/06/2007
Dividend USD 0.15
07/18/2007; 03/09/2007
Dividend USD 0.15
04/18/2007; 01/09/2007
Dividend USD 0.15
01/18/2007; 10/06/2006
Dividend USD 0.15
10/19/2006; 07/06/2006
Dividend USD 0.15
07/20/2006; 04/10/2006
Dividend USD 0.15
04/26/2006

All
Financials
Insiders

About CYCCP

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Webull offers kinds of Cyclacel Pharmaceuticals Inc stock information, including NASDAQ:CYCCP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYCCP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYCCP stock methods without spending real money on the virtual paper trading platform.